To assess the efficacy of targeting the AURKA/YAP1 axis to overcome cetuximab resistance, we measured the cell proliferation changes in cetuximab-resistant CRC cell lines after a combined therapy of 48 hours with alisertib followed by a 72-hour cetuximab treatment. This evidence concerns the gene YAP1 and colorectal carcinoma.